Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed.
atai Life Sciences Presents Phase 1 Study Data on GRX-917
Earlier this year, atai Life Science company GABA Therapeutics announced Positive Final Results from Phase 1 trial of GRX-917. The company has followed-up by presenting data from its trial at the Society for Biological Psychiatry (SOBP) Annual Meeting.
The drug is being developed with the aim to treat conditions like generalized anxiety disorder (GAD), anxious depression, social anxiety disorder (SAD), panic disorder, and postpartum depression.
Mydecine Reports Positive Preclinical Results on MYCO-006 Short-Acting MDMA Analogues
Robert Roscow, CSO of Mydecine:, “Mydecine is happy to have met our development target of developing shorter acting MDMA-like compounds and looks forward to delivering these medications in human trials in the near future. This medication family has tremendous potential to aid people in need.”
Awakn Life Sciences Reports Q4 2023 And Annual Results
Anthony Tennyson, Awakn CEO commented “Awakn made significant progress during the last fiscal year. With safety and efficacy established we are progressing our lead program, AWKN-P001, which targets Severe AUD, into phase III. The majority of the costs for this trial are being paid by the UK state, resulting in this phase III, potentially definitive trial, costing Awakn only $1.25m.
“Additionally, we partnered with a European pharma company to assess repurposing (S)-ketamine into a licenced treatment for addiction, and we are also working with Catalent on a feasibility study of MDMA, leveraging Catalent’s proprietary Zydis® Oral Disintegrating Tablet (ODT) fast dissolve technology, to investigate the possibility of shortening MDMA therapy sessions.”
The UK Parliament Grants Debate on ‘Psilocybin Access Rights’ in the House of Commons
The Conservative Drug Policy Reform Group (CDPRG) has announced that debate on ‘Psilocybin Access Rights’ has been granted in the House of Commons in mid-May.
CDPRG has been working hard on this campaign for the last three years. Very grateful to all 26 MPs from all main parties for their support & commitment.
We look forward to working with them to make the case for HMG to finally follow the evidence & reschedule psilocybin. #PAR 💪 https://t.co/3IEtDyxfYD
— Centre for Evidence Based Drug Policy (@drugpolicyUK) April 27, 2023
Want to catch up on more industry news? Check out a previous edition of the News You Might Have Missed
